Mazor Advances Most Since October on FDA Approval of 3D System

Mazor Robotics Ltd. (MZOR) rose the most in almost two months after it received approval from the U.S. Food and Drug Administration for the three dimensional use of its Renaissance system.

Shares in the developer of surgical robots surged 8.8 percent, the biggest intraday gain since Oct. 17, to 4.227 shekels at 11:16 a.m. in Tel Aviv.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.